Michael Ackermann, PhD

D. Michael Ackermann is the founder and CEO of Osanni Bio. In addition, he serves as Director of Biotechnology for the Stanford University Byers Center for Biodesign. He is a Co-Founder and Board Member of Presidio Medical. He was previously a Co-Founder and Chairman of the Board of Tarsus Pharmaceuticals and Oyster Point Pharma, Inc. (acquired by Viatris in 2023). Prior to this, he was a Vice President of Neurostimulation for Allergan (an AbbVie company), after serving as Co-Founder and CEO of Oculeve, Inc., acquired by Allergan in 2015. Ackermann received a BE degree from Vanderbilt University and MS and a Ph.D. degree from Case Western Reserve University.